Clinical Trials Search

Official Title: A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD-L1-high NSCLC 

Study Purpose: This study will test new combination of experimental drugs, dostarlimab + belrestotug, which have not yet been approved by the FDA.  The study will also evaluate the activity of pembrolizumab given in combination with placebo in lung cancer. Pembrolizumab has been approved by the FDA to treat the type of lung cancer you have been diagnosed with.

Status: Pending

Official Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Study Purpose: To evaluate the efficacy of dostarlimab as sequential therapy following CRT as compared to placebo in participants with PD-L1 positive LA unresected HNSCC 

Status: Recruiting

Official Title: A randomized trial of ultrasound-facilitated, catheter-directed, thrombolysis versus anticoagulation for acute intermediate-high risk pulmonary embolism: The higher-risk pulmonary embolism thrombolysis study.

Study Purpose: To assess whether ultrasound-facilitated, catheter-directed, thrombolysis and anticoagulation are associated with a significant reduction in the composite outcome of pulmonary embolism (PE)-related mortality, cardiorespiratory decompensation or collapse, or nonfatal symptomatic and objectively confirmed recurrence of PE compared to anticoagulation alone within seven days of randomization.

Status: Recruiting

Official Title: A Randomized, Double-blinded, Phase 2/3 Study of HB-202/HB-201 Alternating 2-Vector Therapy in Combination with Pembrolizumab versus Pembrolizumab Alone as First Line Treatment of HPV 16 Positive and High PD-L1 Combined Positive Score Recurrent and/or Metastatic Oropharyngeal Squamous Cell Carcinoma

Study Purpose: To assess antitumor activity and safety of the study drugs, and any impact they may have on survival and quality of life.

Status: Pending

Official Title: A Randomized, Double Blind, Placebo controlled, Phase 2 Study of INBRX 109 as Any line Therapy in Conventional Chondrosarcoma

Study Purpose: To evaluate the anticancer efficacy of INBRX-109 in the intention-to-treat population as measured by progression free survival assessed by central independent radiology review comparing INBRX-109 and placebo.

Status: Recruiting

Official Title: A Multicenter, Randomized, Phase III Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With Standard of Care in Adult participants With Locally Recurrent, InoperaBLE, or Metastatic Soft Tissue Sarcomas - (THE INVINCIBLE-3 TRIAL) 

Study Purpose: To evaluate the effectiveness of IT-03 compared to the usual treatment of pazopanib, trabectedin or eribulin 

Status: Recruiting

Official Title: Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction (LeAAPS) Trial

Study Purpose: To evaluated safety and effectiveness of prophylactic LAAE for the prevention of ischemic stroke or systemic embolism in subjects undergoing cardiac surgery who have risk factors for AF and ischemic stroke

Status: Recruiting

Official Title: DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLOZASIRAN IN ADULTS WITH HYPERTRIGLYCERIDEMIA (MUIR-3 STUDY)

Study Purpose: To demonstrate the efficacy of plozasiran on reducing fasting serum triglyceride levels.

Status: Recruiting

Official Title: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]

Study Purpose: The purpose of the study is to compare two surgical procedures and their ability to decrease the risk of developing ovarian cancer for pre-menopausal women with BRCA1 mutations.

Status: Recruiting

Official Title: Testing Combination Chemotherapy with or without an Investigational Drug or the Investigational Drug Alone for Metastatic Colon or Rectal Cancer

Study Purpose: To learn if adding the experimental agent atezolizumab (MPDL3280A) to the usual treatment or giving the experimental agent alone is better than the usual treatment alone for metastatic colon or rectal cancer.

Status: Recruiting